velpatasvir   Click here for help

GtoPdb Ligand ID: 11269

Synonyms: Epclusa® (sofosbuvir + velpatasvir) | GS-5816 | GS5816 | Vosevi® (sofosbuvir + velpatasvir + voxilaprevi)
Approved drug
velpatasvir is an approved drug (EMA & FDA (2016))
Compound class: Synthetic organic
Comment: Velpatasvir is a direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex [2]. It targets viral RNA replication and viron assembly.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 13
Hydrogen bond donors 4
Rotatable bonds 17
Topological polar surface area 193.1
Molecular weight 882.41
XLogP 5.92
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC[C@H]1C[C@H](N(C1)C(=O)[C@@H](c1ccccc1)NC(=O)OC)c1ncc([nH]1)c1ccc2c(c1)COc1c2cc2ccc3c(c2c1)nc([nH]3)[C@@H]1CC[C@@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C
Isomeric SMILES COC[C@H]1C[C@H](N(C1)C(=O)[C@@H](c1ccccc1)NC(=O)OC)c1ncc([nH]1)c1ccc2c(c1)COc1c2cc2ccc3c(c2c1)nc([nH]3)[C@@H]1CC[C@@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C
InChI InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
InChI Key FHCUMDQMBHQXKK-CDIODLITSA-N
No information available.
Summary of Clinical Use Click here for help
Velpatasvir is used in combination with sofosbuvir, to treat HCV infection.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01740791 Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection Phase 1 Interventional Gilead Sciences 1
External links Click here for help